Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection

Yadav, Pragya; Kumar, Sanjay; Agarwal, K. N.; Jain, Mukul; Patil, Dilip R.; Maithal, Kapil; Mathapati, Basavaraj; Giri, Suresh; Mohandas, Sreelekshmy; Shete, Anita M.; Sapkal, Gajanan; Patil, Deepak Y.; Dey, Ayan; Chandra, Harish; Deshpande, Gururaj; Gupta, Nivedita; Nyayanit, Dimpal A; Kaushal, Himanshu; Sahay, Rima R.; Tripathy, Anuradha S.; Jain, Rajlaxmi; Kumar, Abhimanyu; Sarkale, Prasad; Baradkar, Shreekant; Rajanathan, Chozhavel; Raju, Hari Prasad; Patel, Sachin; Shah, Niraj; Dwivedi, Pankaj; Singh, Dharmendra; Abraham, Priya

doi:10.1101/2021.02.02.429480

Cited by 12 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DNA plasmid construct was transformed into Escherichia coli DH5‐alpha TM chemically competent cells. 131 , 132 , 137 ZyCoV‐D is the first Covid‐19 vaccine approved for young adults older than 12 years. 125 The phase 1 part of the phase 1/2 clinical trial found the DNA vaccine candidate safe and tolerable.…”

Section: Promising Covid‐19 Vaccine Candidatesmentioning

confidence: 99%

Covid‐19 vaccines and variants of concern: A review

Hassine

2021

Reviews in Medical Virology

275

178

View full text Add to dashboard Cite

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid‐19 vaccine candidates based on the original Wuhan‐Hu‐1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid‐19 disease: NVX‐CoV2373 (∼96%), BNT162b2 (∼95%), mRNA‐1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP‐CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS‐CoV‐2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell‐mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid‐19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid‐19 vaccines such as WIBP‐CorV, AD5‐nCOV, ZyCoV‐D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS‐CoV‐2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid‐19 vaccination and introduces some promising Covid‐19 vaccine candidates.

show abstract

Section: Promising Covid‐19 Vaccine Candidatesmentioning

confidence: 99%

Covid‐19 vaccines and variants of concern: A review

Hassine

2021

Reviews in Medical Virology

275

178

View full text Add to dashboard Cite

show abstract

“…It exhibited an efficient immune response. Abdala (CIGB 66), a protein-based vaccine, is under phase 3 clinical trial (Yadav et al 2020 ; Ward et al 2020 ). Medicago is an influenza vaccine that is under trial.…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

COVID-19: comprehensive review on mutations and current vaccines

Hebbani¹,

Pulakuntla

Padmavathi³

et al. 2021

Arch Microbiol

View full text Add to dashboard Cite

Viral outbreaks had been a threat for the human race for a long time. Several epidemics and pandemics have been reported in the past with serious consequences on human health and subsequent social and economic aspects. According to WHO, viral infections continue to be a major health concern globally. Novel coronavirus, SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) causes the most recent infectious pandemic disease, COVID-19 (Coronavirus disease-19). As of now, there were 249 million infections of COVID-19 worldwide with a high mortality of more than 5 million deaths reported; and the number of new additional cases is drastically increasing. Development of therapies to treat the infected cases and prophylactic agents including vaccines that are effective towards different variants are crucial to curtail the COVID-19 pandemic. Owing to the fact that there is a high mortality and morbidity rate along with the risk of virus causing further epidemic outbursts, development of additional effective therapeutic and preventive strategies are highly warranted. Prevention, early detection and treatment will reduce the spread of COVID-19 pandemic. The present review highlights the novel mutations and therapeutic updates associated with coronaviruses along with the clinical manifestations—diagnosis, clinical management and, prophylactic and therapeutic strategies of COVID-19 infection.

show abstract

“…ZyCoV-D, in preclinical studies induced neutralizing antibody response along with Th-1 response and elevated interferon-γ levels. Yadav et al evaluated the immunogenicity and protective efficacy of ZyCoV-D formulations at varying doses in Rhesus macaques [ 102 ]. The vaccine at 2 mg dose successfully induced S1 specific IgG and neutralizing antibody titers, which increased gradually on the viral challenge for up to 2 weeks protecting from lung disease.…”

Section: Vaccines Approved For Public Usementioning

confidence: 99%

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

et al. 2021

View full text Add to dashboard Cite

The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019 (COVID-19) pandemic worldwide. Given its unprecedented infectivity and pathogenicity, the COVID-19 pandemic had a devastating impact on human health, and its clinical management has been a great challenge, which has led to the development and speedy trials of several vaccine candidates against SARS-CoV-2 at an exceptional pace. As a result, several COVID-19 vaccines were made commercially available in the first half of 2021. Although several COVID-19 vaccines showed promising results, crucial insights into their epidemiology, protective mechanisms, and the propensities of reinfection are not largely reviewed. In the present report, we provided insights into the prospects of vaccination against COVID-19 and assessed diverse vaccination strategies including DNA, mRNA, protein subunits, vector-based, live attenuated, and inactivated whole/viral particle-based vaccines. Next, we reviewed major aspects of various available vaccines approved by the World Health Organization and by the local administrations to use against COVID-19. Moreover, we comprehensively assessed the success of these approved vaccines and also their untoward effects, including the possibility of reinfection. We also provided an update on the vaccines that are under development and could be promising candidates in the future. Conclusively, we provided insights into the COVID-19 vaccine epidemiology, their potency, and propensity for SARS-CoV-2 reinfection, while a careful review of their current status, strategies, success, and future challenges was also presented.

show abstract

Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection

Cited by 12 publications

References 38 publications

Covid‐19 vaccines and variants of concern: A review

Covid‐19 vaccines and variants of concern: A review

COVID-19: comprehensive review on mutations and current vaccines

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

Contact Info

Product

Resources

About